DIRS.INFO The most relevant business & tech news

☆ The 13 startups to watch in the $100 billion market for buzzy new weight-loss drugs like Ozempic
▼ + stars: | 2023-04-11 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +3 min

Healthcare startups are launching to prescribe weight-loss drugs such as Ozempic. They're chasing what's projected to be a $100 billion market for the drugs. Venture-backed health startups are vying for a piece of the booming market for new prescription drugs designed to help with weight loss. Many startups offering weight-loss drugs have flooded social media platforms with ads for the shots. Insider rounded up 13 venture-backed startups competing for customers in the lucrative GLP-1 weight-loss market, listed from least to most funding raised.

☆ FDIC retains BlackRock unit for Signature Bank, SVB securities portfolio sale
▼ + stars: | 2023-04-05 | by ( ) www.reuters.com time to read: +1 min

April 5 (Reuters) - The Federal Deposit Insurance Corporation (FDIC) has retained BlackRock Inc (BLK.N) unit Financial Market Advisory to sell the securities portfolios it kept in receivership after the collapse of Signature Bank and Silicon Valley Bank. The face values of the two portfolios are about $27 billion and $87 billion, the regulator said in a statement on Wednesday. Reuters earlier reported that the FDIC retained advisers to sell the securities portfolios that the new owners of the two banks had rejected. On Monday, the FDIC announced the marketing process for an about $60 billion loan portfolio retained in receivership following the failure of Signature Bank. The securities are primarily comprised of agency mortgage-backed securities, collateralized mortgage obligations and commercial mortgage-backed securities, the FDIC said on Wednesday.

☆ 13 startups vying for a slice of the $100 billion market for buzzy new weight-loss drugs
▼ + stars: | 2023-04-05 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +3 min

☆ Here are Monday's biggest analyst calls: Tesla, Amazon, First Republic, Roku, Walmart & more
▼ + stars: | 2023-03-27 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Here are Monday's biggest calls on Wall Street: Susquehanna upgrades Roku to positive from neutral Susquehanna said it sees an attractive risk/reward for the stock. Citi upgrades KeyCorp and M & T Bank to buy from neutral Citi upgraded several regional banks on Monday and said the risk/reward looks compelling. Morgan Stanley reiterates Amazon as overweight Morgan Stanley said it sees 50% upside for shares of the e-commerce giant. Morgan Stanley reiterates Walmart as overweight Morgan Stanley said it sees an attractive risk/reward heading into the company's investment community meeting on April 4. Morgan Stanley moves First Republic to no rating Morgan Stanley removed its estimates and ratings on the stock due to too much uncertainty.

☆ The banking crisis has college students on edge about Wall Street jobs and internships. 'I just want to know what the plan is.'
▼ + stars: | 2023-03-27 | by ( Emmalyse Brownstein | ) www.businessinsider.com time to read: +6 min

That's the concern plaguing aspiring investment bankers across the country as they watch the banking crisis unfold. "I think there's definitely a sense of unease in finance," said Asif Rahman, co-founder of Wall Street career coaching company Office Hours. Over at SVB's investment banking arm, incoming first-year analysts have been told that their jobs are secure. "We've reached out to all of our incoming analysts and interns. "The incoming summer interns are worried about low return offer rates," the professor said.

☆ Drug developer 89Bio soars as NASH drug succeeds in mid-stage study
▼ + stars: | 2023-03-22 | by ( ) www.reuters.com time to read: +2 min

March 22 (Reuters) - Drug developer 89Bio Inc <ETNB.O> said on Wednesday its experimental treatment for liver disease NASH met the main goals of a small mid-stage study, sending its shares 30% higher. The drug, pegozafermin, helped reduce liver scarring known as fibrosis as measured on two different scales in patients with NASH, or nonalcoholic steatohepatitis, trial data showed. 89Bio said the drug, administered both weekly and every two weeks in the trial, had a safety profile similar to older trials. In the trial, the drug helped significantly reduce fibrosis or liver scarring without the worsening of NASH, compared to a placebo. NASH, a form of non-alcoholic fatty liver disease, is characterized by the organ developing fibrosis or scarring, which can progress to cirrhosis and liver failure.

March 20 (Reuters) - SVB Financial Group (SIVB.O) on Monday filed a number of "First Day Motions" to seek authorization from a bankruptcy court to support the operations of the company's SVB Capital and SVB Securities businesses. Reporting by Manya Saini in Bengaluru; Editing by Arun KoyyurOur Standards: The Thomson Reuters Trust Principles.

☆ Silicon Valley Bank's parent company cut off from bank's records
▼ + stars: | 2023-03-20 | by ( Dietrich Knauth | ) www.reuters.com time to read: +3 min

SVB Financial has no employees of its own, and the new bank's employees "cut off access" to a substantial portion of SVB Financial's "books, records, files, electronic systems and key employees," according to Kosturos. The FDIC receivership removed SVB Financial's primary source of liquidity and most of its business infrastructure, as well as triggering defaults on SVB Financial's debt, forcing the company into bankruptcy, according to court documents. SVB Financial's court filings listed $19 billion in assets, $2.2 billion in cash and cash equivalents, and $3.4 billion in liabilities. About $15.5 billion of SVB Financial's asset value was attributed to the SVB banking business that was seized by regulators. Those investment funds include direct venture funds that invest in companies, funds-of-funds that invest in other venture capital funds, and debt funds that provide lending and other financing solutions to startups.

☆ SVB Financial seeks bankruptcy protection
▼ + stars: | 2023-03-17 | by ( ) www.reuters.com time to read: +1 min

March 17 (Reuters) - SVB Financial Group (SIVB.O) said on Friday it planned to seek bankruptcy protection among other restructuring alternatives to seek buyers for its assets, days after its former unit Silicon Valley Bank was taken over by U.S. banking regulators. SVB Securities and SVB Capital's funds and general partner entities are not included in the Chapter 11 filing, the company said. The plan to seek bankruptcy protection comes after the tech lender said on March 13 it was planning to explore strategic alternatives for its businesses, including the holding company, SVB Capital and SVB Securities. California banking regulators closed the bank on Friday and appointed the Federal Deposit Insurance Corporation (FDIC) as receiver for later disposition of its assets. Reporting by Mehnaz Yasmin in Bengaluru; Editing by Sriraj KalluvilaOur Standards: The Thomson Reuters Trust Principles.

"Not only are these big banks not sitting around and waiting for the phone to ring, they are also being proactive." Amid the nation's most troubling turmoil in banking since the global financial crisis nearly 15 years ago, the big banks are flexing their collective muscle. The 2008 financial crisis humbled the banking behemoths; the 2023 crisis of regional banks has now only cemented their power. For an increasingly stretched financial system, the big banks provide a needed stability. The flight to safety that is benefiting the big banks will have a cost, however.

☆ SVB Financial seeks bankruptcy protection for reorganization
▼ + stars: | 2023-03-17 | by ( ) www.reuters.com time to read: +1 min

March 17 (Reuters) - SVB Financial Group (SIVB.O) said on Friday it filed for a court-supervised reorganization under Chapter 11 bankruptcy protection to seek buyers for its assets, days after its former unit Silicon Valley Bank was taken over by U.S. regulators. The plan to seek bankruptcy protection comes after the company said on March 13 it was planning to explore strategic alternatives for its businesses, including the holding company, SVB Capital and SVB Securities. SVB Securities and SVB Capital's funds and general partner entities are not included in the Chapter 11 filing, the company said on Friday. Reuters reported on Wednesday that the parent company was exploring seeking bankruptcy protection for selling assets. California banking regulators closed SVB on Friday and appointed the Federal Deposit Insurance Corporation as receiver for later disposition of its assets.

☆ Private equity giants including Apollo, Blackstone eye SVB loan book- reports
▼ + stars: | 2023-03-14 | by ( ) www.reuters.com time to read: +2 min

[1/2] Customers wait outside as an employee enters the Silicon Valley Bank branch office in downtown San Francisco, California, U.S., March 13, 2023. REUTERS/Kori Suzuki/File PhotoMarch 14 (Reuters) - Apollo Global Management Inc (APO.N), Blackstone Inc (BX.N) and KKR & Co Inc (KKR.N) have expressed interest in a book of loans held by Silicon Valley Bank (SVB), Bloomberg News reported on Tuesday, citing people familiar with the matter. Buyout giants Ares Management (ARES.N) and Carlyle Group (CG.O) are also looking to buy the loan book, the Financial Times reported, citing people familiar with the matter. The surge in interest in the book follows the tech lender's failure last week to raise equity to plug a $1.8 billion hole after selling its $21 billion portfolio of securities at a loss. On Monday, SVB said it was planning to explore strategic alternatives for its businesses, including holding company SVB Capital and SVB Securities.

☆ How buzzy weight-loss drugs like Ozempic became the next craze in the hottest part of healthcare
▼ + stars: | 2023-03-14 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +7 min

Healthcare companies are launching programs left and right to prescribe trendy weight-loss drugs. And Ro, a startup that prescribes and sells products like Viagra and hair-loss pills to consumers, is going all in with a program it launched in January to prescribe the weight-loss drugs to patients online. CalibrateFirst developed to manage type 2 diabetes, GLP-1 medications regulate blood-sugar levels, which can help people curb cravings and feel fuller after eating. The weight-loss market for GLP-1 drugs is relatively new, and not everyone is on board. But for some companies, stepping into prescribing these new weight-loss medications seems to simply be the natural next step for growth.

☆ SVB Financial Group mulls strategic alternatives
▼ + stars: | 2023-03-13 | by ( ) www.reuters.com time to read: 1 min

March 13 (Reuters) - Defunct startup-focused lender SVB Financial Group (SIVB.O) said on Monday that it was planning to explore strategic alternatives for its businesses, including the holding company, SVB Capital and SVB Securities. The move comes after Californian regulators shuttered the bank following a failed share sale that drained $42 billion in deposits in a single day and sucked out liquidity at the company. Its board has appointed a restructuring committee consisting of five independent directors, it said in a statement. Reporting by Mehnaz Yasmin in Bengaluru; Editing by Anil D'SilvaOur Standards: The Thomson Reuters Trust Principles.

☆ Why buzzy weight-loss drugs are the next craze for healthcare startups
▼ + stars: | 2023-03-13 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +7 min

Healthcare companies are launching programs left and right to prescribe trendy weight-loss drugs. And Ro, a startup that prescribes and sells products like Viagra and hair-loss pills to consumers, is going all in with a program it launched in January to prescribe the weight-loss drugs to patients online. Even startups like Noom, which quietly started a program prescribing GLP-1 medications, could stand to benefit from the drugs' popularity after a tumultuous year for the startup. The weight-loss market for GLP-1 drugs is relatively new, and not everyone is on board. But for some companies, stepping into prescribing these new weight-loss medications seems to simply be the natural next step for growth.

☆ SVB is still looking for a buyer. Here is what we know so far.
▼ + stars: | 2023-03-13 | by ( Hayley Cuccinello | ) www.businessinsider.com time to read: +5 min

The weekend came and went without a buyer for SVB Financial Group, the parent company of the failed Silicon Valley Bank. SVB Capital focuses on venture capital and credit investing and SVB Securities is its investment banking arm. Axios reported Monday morning that JPMorgan and PNC were in talks to acquire SVB Financial Group but not the failed commercial bank. SVB Securities, better known as SVB Leerink, the investment banking arm born out of SVB's 2018 acquisition of Leerink, is a very desirable business, he added. "SVB Leerink is a well-known name in the tech and healthcare space that will be attractive to someone," said Healy.

☆ Silicon Valley Bank’s investment banking arm explores buying firm back -Bloomberg News
▼ + stars: | 2023-03-12 | by ( ) www.reuters.com time to read: 1 min

March 11 (Reuters) - The managers of Silicon Valley Bank’s (SIVB.O) investment banking arm, SVB Securities Management, are exploring ways to buy the firm back from its parent, Bloomberg News reported on Saturday, citing people familiar with the matter. The head of SVB Securities, Jeff Leerink, and his team are seeking help to finance a potential management buyout of the business, the report said, adding that they are rushing to do a speedy deal as regulators seek a buyout for the remnants of SVB Financial Group. Reporting by Kanjyik Ghosh in Bengaluru; editing by Grant McCoolOur Standards: The Thomson Reuters Trust Principles.

☆ How SVB employees are coping after being ordered to leave the office, from polishing their resumes to hitting the bar: 'We're pretty much in the dark'
▼ + stars: | 2023-03-10 | by ( Emmalyse Brownstein | Rebecca Ungarino | Carter Johnson | ) www.businessinsider.com time to read: +6 min

It read: "Operations of the SVB Securities broker dealer are distinct from the receivership of SVB Financial." The SVB Securities employee called the whirlwind leading up to SVB's meltdown as "scary, scary stuff." Kevin Heal, senior analyst at Argus Research, said he sees both SVB Securities and SVB Private being sold. SVB bought the healthcare investment bank Leerink Partners in 2018, renaming it SVB Leerink and then SVB Securities. PATRICK T. FALLON/AFP via Getty ImagesHeal thinks the investment banking operations could be purchased by a smaller investment banking firm that doesn't have tech or healthcare prowess, like US Bancorp or PNC.

☆ Reata shares triple after surprise FDA nod for rare disease drug
▼ + stars: | 2023-03-01 | by ( ) www.reuters.com time to read: +2 min

March 1 (Reuters) - Shares of Reata Pharmaceuticals Inc (RETA.O) tripled in value on Wednesday after the U.S. Food and Drug Administration (FDA) approved its rare disease drug, ending years of uncertainty over its future. The U.S. biotech firm's shares jumped to $93, the highest since late 2021, on more than 16 million shares traded, a record one-day volume for the stock. Reata's drug Skyclarys is the first approved treatment for Friedreich's Ataxia, a rare genetic disorder that causes progressive damage to the nervous system and can lead to premature death. The nod follows years of back and forth between Reata and the FDA. Reata's shares had tumbled 30% following Dunn's resignation as investors fretted about the possibility of approval under a new division head.

☆ Reata shares hit 1-year high after surprise FDA nod for rare disease drug
▼ + stars: | 2023-03-01 | by ( ) www.reuters.com time to read: +2 min

March 1 (Reuters) - Shares of Reata Pharmaceuticals Inc (RETA.O) soared 175% to hit a one-year high in early trading on Wednesday, after the U.S. Food and Drug Administration (FDA) approved its rare disease drug and ended years of uncertainty over its future. The U.S. biotech firm's shares jumped to $86, their highest since December 2021. The nod follows years of back and forth between Reata and the FDA. Reata's shares had tumbled 30% following Dunn's resignation as investors had fretted about the possibility of approval under a new division head. "We've followed some pretty dramatic stories in the past, but the Reata odyssey is in the Hall of Fame," said Baird analyst Brian Skorney.

☆ Jim Cramer's top 10 things to watch in the stock market Friday: Hot inflation — bond yields up and stocks down
▼ + stars: | 2023-02-24 | by ( Jim Cramer | ) www.cnbc.com time to read: +5 min

As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. ET: Jim and Jeff discuss the Club portfolio (Part 1)12:15--1:30 p.m. ET: Jim and Jeff discuss the portfolio (Part 2)2:15-2:45 p.m.

☆ Here are Thursday's biggest analyst calls: Tesla, Apple, Intel, Teladoc, Nvidia, Salesforce & more
▼ + stars: | 2023-02-23 | by ( Michael Bloom | ) www.cnbc.com time to read: +8 min

Bank of America reiterates Target as neutral Bank of America said it sees "modest upside" at current levels. Bank of America downgrades Lucid Group to neutral from buy Bank of America said it's concerned about slowing demand for the luxury vehicle company. Bank of America reiterates Nvidia as buy Bank of America said Nvidia remains "best-in-class" after its earnings report on Wednesday. Bank of America reiterates CVS as buy Bank of America said it sees "significant free cash flow generation potential" for CVS. Goldman Sachs upgrades Nvidia to buy from neutral Goldman upgraded Nvidia after its "impressive" earnings report on Wednesday.

☆ Here are Friday's biggest analyst calls: Tesla, Target, Micron, Walmart, Lyft, Affirm, Roku & more
▼ + stars: | 2023-02-10 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Bank of America downgrades Deutsche Bank to underperform from neutral Bank of America said it sees waning profitability for the European banking giant. Jefferies reiterates Walmart as buy Jefferies said it's standing by its buy rating on the stock heading into earnings later this month. Guggenheim reiterates Target as buy Guggenheim says it's standing by shares of the e-commerce giant heading into earnings later this month. Oppenheimer reiterates Roku as outperform Oppenheimer said it's standing by its outperform rating on shares of Roku. Bank of America initiates Freyr Battery as buy Bank of America said it sees an attractive risk/reward for the battery company. "

☆ Tenet Healthcare's fourth-quarter beat puts 2023 concerns at bay
▼ + stars: | 2023-02-09 | by ( ) www.reuters.com time to read: +2 min

Feb 9 (Reuters) - Tenet Healthcare Corp (THC.N) on Thursday beat Wall Street estimates for fourth-quarter results as growth in its outpatient service business put concerns around the hospital operator's weak 2023 forecast at bay. HCA Healthcare also recently forecast lower-than-expected 2023 profit, but bet on improved staffing trends and lower labor costs to drive growth for the year. "As expected, the 2023 forecast came in below consensus estimates, but we believe investors had already priced that in," SVB Securities analyst Whit Mayo said. Tenet is betting on growth in its ambulatory care unit, which deals with patients who are not bedridden and don't require overnight hospitalization. On an adjusted basis, Tenet reported a net income of $1.96 per share for the quarter ended Dec. 31, beating estimates of $1.23 per share.

☆ AbbVie's 2023 profit forecast misses as Humira faces heat from rivals
▼ + stars: | 2023-02-09 | by ( ) www.reuters.com time to read: +2 min

Most analysts are expecting the stock to be driven by management's comments on Humira sales this year during the investor conference call. AbbVie's weak forecast suggests that Humira rivals could nibble away at the blockbuster drug's market share at a faster pace this year than analysts' projections. In the fourth quarter, Humira sales dropped 26.5% to $573 million in international markets such as Europe, where it already faces competition from multiple cheaper versions. Overall, Humira sales rose 4.6% to $5.58 billion, in line with estimates, lifted by growth in the U.S. market. Excluding items, AbbVie earned $3.60 per share in the fourth quarter, beating analysts' average estimates of $3.56 per share.

Search resuls for: "SVB Securities"

25 mentions found